BR112023018932A2 - Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular - Google Patents

Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular

Info

Publication number
BR112023018932A2
BR112023018932A2 BR112023018932A BR112023018932A BR112023018932A2 BR 112023018932 A2 BR112023018932 A2 BR 112023018932A2 BR 112023018932 A BR112023018932 A BR 112023018932A BR 112023018932 A BR112023018932 A BR 112023018932A BR 112023018932 A2 BR112023018932 A2 BR 112023018932A2
Authority
BR
Brazil
Prior art keywords
formulation
ocular
pharmaceutically acceptable
ocular administration
treatment
Prior art date
Application number
BR112023018932A
Other languages
English (en)
Inventor
Andreas Buhl
Hans WÄNNMAN
Helena Eriksson
Marie Törngren
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR112023018932A2 publication Critical patent/BR112023018932A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular. uma formulação farmacêutica compreendendo laquinimode ou um sal farmaceuticamente aceitável do mesmo como ingrediente ativo, um agente de viscosidade farmaceuticamente aceitável, um agente de ajuste de tonicidade farmaceuticamente aceitável, um umectante farmaceuticamente aceitável, um antioxidante farmaceuticamente aceitável e um agente regulador de ph farmaceuticamente aceitável. a formulação é adequada para o tratamento de doenças oculares por administração ocular, preferivelmente administração ocular tópica.
BR112023018932A 2021-04-01 2022-03-31 Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular BR112023018932A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166691 2021-04-01
PCT/EP2022/058523 WO2022207773A1 (en) 2021-04-01 2022-03-31 Laquinimod formulation for ocular use

Publications (1)

Publication Number Publication Date
BR112023018932A2 true BR112023018932A2 (pt) 2023-10-10

Family

ID=75362492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018932A BR112023018932A2 (pt) 2021-04-01 2022-03-31 Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular

Country Status (11)

Country Link
US (1) US20240180819A1 (pt)
EP (1) EP4312986A1 (pt)
JP (1) JP2024516929A (pt)
KR (1) KR20230165260A (pt)
CN (1) CN117120035A (pt)
AU (1) AU2022248724A1 (pt)
BR (1) BR112023018932A2 (pt)
CA (1) CA3212851A1 (pt)
IL (1) IL305997A (pt)
MX (1) MX2023010971A (pt)
WO (1) WO2022207773A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2015073697A1 (en) 2013-11-15 2015-05-21 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
BR112022009192A2 (pt) 2019-12-19 2022-07-26 Active Biotech Ab Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto

Also Published As

Publication number Publication date
CA3212851A1 (en) 2022-10-06
EP4312986A1 (en) 2024-02-07
JP2024516929A (ja) 2024-04-18
US20240180819A1 (en) 2024-06-06
CN117120035A (zh) 2023-11-24
AU2022248724A1 (en) 2023-11-02
WO2022207773A1 (en) 2022-10-06
IL305997A (en) 2023-11-01
KR20230165260A (ko) 2023-12-05
MX2023010971A (es) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BRPI0608152A2 (pt) formulações para tratamento ocular
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
AU2020213351B2 (en) Methods of treating ocular conditions
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
KR20190024593A (ko) 수면장애 예방 또는 치료용 조성물
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
KR20170018852A (ko) 상처 치료를 위한 국소 조성물 및 방법
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
Weil et al. The use of lidocaine patches
BR112023018932A2 (pt) Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular
WO2018031216A1 (en) Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
JP7191022B2 (ja) アルカフタジン又はその塩を含有する水性医薬組成物
BR112021000183A8 (pt) Preparação medicinal para uso externo
BRPI0408113A (pt) métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica
AU2014216273A1 (en) Topical ocular analgesic agents
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
JP6996775B2 (ja) 個体の毛髪の成長を促進する、毛髪の抜けを予防する、または個体の毛包幹細胞の生成を促進する薬物の調製における組成物の用途
ES2659458T3 (es) Compuestos de naftaleno para tratar el prurito
BR112022017856A2 (pt) Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
BR112023004354A2 (pt) Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico